AstraZeneca Says US Approved Lynparza as a Prostate Cancer Treatment
01 Junho 2023 - 3:49AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca said Thursday that its and MSD's Lynparza cancer
treatment had been approved in the U.S. for the treatment of
metastatic castration-resistant prostate cancer, or mCRPC.
The Anglo-Swedish pharma giant said Lynparza, in combination
with abiraterone and prednisone, reduced the risk of disease
progression or death by 76% versus abiraterone alone.
The company said the approval was based on a subgroup analysis
of the phase 3 PROpel trial.
This Lynparza combination is approved in the EU and several
other countries for the treatment of adult patients with mCRPC
based on the PROpel trial, it said.
AstraZeneca said that following this approval in the U.S. it
will receive a regulatory milestone payment from MSD, anticipated
to be booked as collaboration revenue by the company and confirmed
in the second quarter 2023 results.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 01, 2023 02:34 ET (06:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
